1例EGFR T790突变肺腺癌晚期患者使用AZD9291临床治疗实践被引量：1

Clinical practice of AZD9291 in a patient with advanced lung adenocarcinoma by EGFR T790 mutant: a case report

导出

摘要目的:探讨晚期非小细胞肺癌患者服用表皮生长因子受体酪氨酸激酶抑制剂(epithelial growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIs)后的耐药机制,疗效指标以及与其他药物间的相互作用。方法:本文分析了1例服用吉非替尼耐药后行EGFR T790M基因检测呈阳性的肺腺癌晚期患者的病情及用药情况,通过相关基因检测及查阅文献,探讨其耐药机制,腹泻处理和质子泵抑制剂之间的相互作用及解决方案。结果:根据患者的基因型、腹泻原因选择了最佳给药方案,最终使患者癌细胞及腹泻情况得以控制。结论:临床药师从多角度全面分析了EGFRTKIs的影响因素,为临床合理用药提供参考,确保临床治疗的安全性及有效性。 Objective：To investigate the mechanism,efficacy,and drug-drug interactions in patients with advanced non-small cell lung cancer （NSCLC） treated with EGFR-TKI.Methods：This paper analyzes the condition and medication in patients with advanced lung adenocarcinoma after administration of gefitinib resistance caused by EGFRT790M gene positive.Through genetic testing and literature review,this paper tried to explore the mechanism of drug resistance,diarrhea treatment and the interaction between proton pump inhibitors and gefitinib.Results：According to the patient＆#39;s genotype and diarrhea,the optimal dosing regimen was selected,and the cancer cells and diarrhea were finally controlled.Conclusion：Clinical pharmacists analyzed the influencing factors of EGFR-TKIs from multiple perspectives,and provided reference for clinical rational drug use to ensure the safety and effectiveness of clinical treatment.

作者陈婧谌介秀王卓张文静

机构地区上海长海医院药学部临床药学室新疆军区总医院药剂科临床药学室

出处《临床药物治疗杂志》 2017年第6期72-75,共4页 Clinical Medication Journal

基金上海市卫生计生系统重要薄弱学科建设计划项目(编号:2016ZB0303-01)

关键词非小细胞肺癌 EGFR-TKI T790 吉非替尼 AZD9291 non-small cell lung cancer epidermal growth factor receptor-tyrosine kinase inhibitor T790 gefitinib AZD9291

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献2

1许阳,陈良安.表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌患者原发性耐药机制的研究进展[J].解放军医学院学报,2013,34(4):418-420. 被引量：5
2洪群英,白春学.晚期非小细胞肺癌表皮生长因子受体-酪酸激酶抑制剂靶向治疗进展[J].世界临床药物,2012,33(4):197-201. 被引量：8

二级参考文献39

1Ciuleanu T,Stelmakh L,Cicenas S. Efficacy of secondline erlotinib versus chemotherapy relative to biomarker status in the phase Ⅲ global TITAN study in advanced nonsmall-cell lung cancer (NSCLC).2011 WCLC,Oral Session,[O10.03]Medical Oncology Ⅰ[M].
2Ahn M,Sun J,Lee K. Randomized phase Ⅲ trial of gefitinib or pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01).2011 WCLC,Oral Session,[O10.04].Medica Oncology Ⅰ[M].
3Gridelli C,Butts C,Ciardiello F. An international,multicenter,randomized phase Ⅲ study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus firstline cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer:treatment rationale and protocol dynamics of the TORCH trial[J].Clinical Lung Cancer,2008,(04):235-238.doi:10.3816/CLC.2008.n.037.
4Lee JS,Park K,Kim S-W. A randomized phase Ⅲ study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung[A].San Francisco,CA,USA,2009.
5Mitsudomi T,Morita S,Yatabe Y. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):An open label,randomized phase 3 trial[J].Lancet Oncology,2010,(02):121-128.doi:10.1016/S1470-2045(09)70364-X.
6Zhou C,Wu Y,Chen G. Efficacy results from the randomised phase Ⅲ OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine,in chinese advanced non-small-cell lung cancer patients with EGFR activating mutations[A].
7Zhou C,Wu Y,Chen G. Updated median PFS and analysis of qua ity of life (QOL) in OPTIMAL,a phase Ⅲ,randomized,open-label,first line study of erlotinib vs carboplatin/gemcitabine in patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations[A].
8Gervais R,Rosell R,Vergnenegre A. The EURTAC (European Tarceva(R) vs Chemotherapy) study:interim results of a phase Ⅲ randomized trial of erlotinib vs chemotherapy (CT)in advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) activating mut[A].
9Hida T,Okamoto I,Kashii T. Randomized phase Ⅲ study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC):Results of West Japan Thoracic Oncology Group trial (WJTOG0203)[J].Journal of Clinical Oncology,2010,(05):753-760.
10Miller VA,O'Connor P,Soh C. A randomized,double-blind,placebo-controlled,phase Ⅲb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E)after completion of chemotherapy with B for first-line treatment of locally advanced,recurrent,or metastatic non-small cell lung cancer (NSCLC)[J].Journal of Clinical Oncology,2009,(18s):abstrLBA8002.